According to Forbes, the decentralized derivatives platform Hyperliquid has launched the pre-IPO perpetual contract for SpaceX (SPCX-USDC) on Trade.xyz, sparking a global regulatory gray area controversy. This contract allows leveraged trading without holding any shares of SpaceX and has not been authorized by the company, with an initial reference price of $150, corresponding to an implied valuation of approximately $1.78 trillion, which quickly surged to $216.
It is reported that this contract is settled in USDC, with prices derived from market oracles, and is not linked to SpaceX's actual financials or equity structure. SpaceX itself has neither authorized nor participated in this market, yet its valuation is being priced and traded in real-time on-chain, leading to the controversy of "private company price discovery being taken over by decentralized derivatives." This market originates from Hyperliquid's HIP-3 mechanism, which supports the notion that the valuations of private companies may be being repriced by on-chain derivatives, while the regulatory framework has yet to be established.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


Key Takeaways Tether has become a significant player in the US Treasuries market, ranking as the 17th-largest holder…

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.












Key Takeaways Tether has become a significant player in the US Treasuries market, ranking as the 17th-largest holder…
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.